Human Longevity, Inc. Appoints Key Oncology Leader, Kenneth J. Bloom, M.D., to Head Oncology and Immunotherapy Program

- February 4th, 2016

Human Longevity, Inc. (HLI) announced today the appointment of several key people for its oncology genomics program.

Human Longevity, Inc. (HLI) announced today the appointment of several key people for its oncology genomics program.
According to the company’s press release:

Kenneth J. Bloom, M.D. will join the company as the new head of oncology and immunotherapy; Stephen P. Schoenberger, Ph.D. will lead cancer vaccine efforts and Ezra Cohen, M.D., who is also Associate Director and Professor of Medicine, Moores Cancer Center, University of California, San Diego, will be a staff oncologist.

J. Craig Venter, Ph.D., Co-founder and CEO, HLI commented:

We are excited to have Ken, Stephen and Ezra on the HLI team and are confident their combined clinical and scientific expertise will greatly enhance our oncology program. We have been working over the last year on developing our oncology program with help from Ezra. We will look to Ken and his team to further develop and commercialize this important area of our business.

Click here to view the full release.

Leave a Reply